Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Organisation › Details

Vaximm AG

VAXIMM is a privately held, Swiss- and German-based biotech company that is primarily focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Its initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. VXM01 has shown impressive anti-tumor activity in various animal studies and human clinical trials are expected to start in 2011. VAXIMM was formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA to develop VXM01. Vaximm GmbH is a fully owned subsidiary of VAXIMM AG, with offices in Mannheim, Germany. *


Period Start 2011-01-15 existent
  Group Vaximm (Group)
  Predecessor Merck KGaA
Products Industry therapeutic vaccine
  Industry 2 VXM01 cancer vaccince
Region Region Basel BS
  Country Switzerland
  Street 3 Elisabethenstr.
  City 4051 Basel BS
    Address record changed: 2011-05-14
Basic data Employees n. a.
    * Document for �About Section�: Vaximm AG. (1/12/11). "Press Release: Vaximm Closes CHF 7.8 Million Financing Round". Basel & Mannheim.
Record changed: 2017-05-26


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Vaximm (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top